Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Salden, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salden, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:327-332, 2000
© 2000 European Society for Medical Oncology

research-article

The urokinase-type plasminogen activator system in resected non-small-cell lung cancer

M. Salden1, T. A. W. Splinter1, H. A. Peters1, M. P. Look1, M. Timmermans1, J. P. A. M. van Meerbeeck2, J. A. Foekens1, on behalf of the Rotterdam Oncology Thoracic Study Group

1Laboratory of Tumour Endocrinology, Department of Medical Oncology, University Hospital Rotterdam Rotterdam, The Netherlands
2Laboratory of Tumour Endocrinology, Department of Pulmonology, University Hospital Rotterdam Rotterdam, The Netherlands

Correspondence to: J. A. Foekens, MD, Josephine Nefkens Institute, RM Be426, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands, E-mail: foekens{at}bidh.azr.nl

Background: Urokinase-type plasminogen activator (uPA), its receptor (uPAR) and plasminogen activator inhibitors (PAI-1 and PAI-2), all play important roles in tumour invasion and metastasis. The tumour levels of the components of the urokinase-type plasminogen activator system (uPA-system) may help to identify individuals with a poor prognosis in post-operative non-small-cell lung cancer (NSCLC) patients.

Patients and methods: The levels of uPA, uPAR PAI-1 and PAI-2 were measured by enzyme-linked immunosorbent assay (ELISA) in triton-extracts, prepared from 88 NSCLC tissues (stage I–IIIa) and 74 normal lung tissues from the same patients.

Results: The expression levels of uPA, uPAR, PAI-1 and PAI-2 were significantly higher in tumour tissues as compared to their normal equivalents (all, P < 0.0001). Significant relations were found between gender and uPA (P = 0.04) or uPAR (P < 0.001), and between PAI-2 and pathological stage (P = 0.03). For none of the studied factors of the uPA-system a significant relation with survival was found, neither in all patients, nor in the subgroups of patients with squamous-cell lung carcinoma or adenocarcinoma.

Conclusions: The expression levels of the components of the uPA-system were higher in NSCLC tissue as compared to normal lung tissue, but there were no significant relationships between their levels and survival.

non-small-cell lung cancer, PAI-1, PAI-2, uPA, uPAR


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. P. Mazar
Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy
Clin. Cancer Res., September 15, 2008; 14(18): 5649 - 5655.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Pakneshan, B. Tetu, and S. A. Rabbani
Demethylation of Urokinase Promoter as a Prognostic Marker in Patients with Breast Carcinoma
Clin. Cancer Res., May 1, 2004; 10(9): 3035 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 CLIN APPL THROMB HEMOSTHome page
E. Cobos, C. Jumper, and C. Lox
Pretreatment Determination of the Serum Urokinase Plasminogen Activator and its Soluble Receptor in Advanced Small-Cell Lung Cancer or Non-Small-Cell Lung Cancer
Clinical and Applied Thrombosis/Hemostasis, July 1, 2003; 9(3): 241 - 246.
[Abstract] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. A. D'Amico, T. A. Aloia, M.-B. H. Moore, D. H. Conlon, J. E. Herndon II, M. S. Kinch, and D. H. Harpole Jr
Predicting the sites of metastases from lung cancer using molecular biologic markers
Ann. Thorac. Surg., October 1, 2001; 72(4): 1144 - 1148.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.